Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!What’s on Tap in Our 6 Pack Episode?Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:New Therapy for Recessive Dystrophic Epidermolysis Bullosa: We’re walking through the latest clinical trial that could be a real gamechanger.Homemade vs. Commercial Sunscreens: Should your patients blend SPF cocktails in the kitchen, or is that a recipe for disaster?Immunosuppressives and Patch Testing: Just how “immunosuppressed” can your patients be and still get valid patch testing results? We’ve got the hottest updates from the experts—no immuno-anxiety required.HPV Vaccine vs. Actinic Keratoses: A blockbuster therapy for warty issues? This clinical trial investigates the HPV vax as a new weapon in the fight against actinic keratoses.Hailey-Hailey Disease Treatment Algorithms: Confused by this rare disease? We’re breaking down shiny new algorithms so you can manage it like a pro.JAK Inhibitor Discontinuation and Heart Risks: Why do patients sometimes trade clear skin for cardiac drama after stopping a JAK inhibitor? The science just got spicier, and we’ve got the scoop.So scrub in, sit back, and let us put the “fun” in fundamentals as we break down the latest, greatest (and occasionally weirdest) in the world of clinical dermatology. Let’s pop open that six-pack and get started.And for links to all of the articles we discussed in this episode, visit ScholarsInMedicine.com
--------
38:44
--------
38:44
Blistering Breakthroughs: Dupilumab’s Big Debut
Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:Review three of the hottest papers on bullous pemphigoid, dissecting the latest evidence with our signature blend of rigor and irreverence.Break down the recent FDA approval of dupilumab for bullous pemphigoid—a new kid on the blister block!Unpack the pivotal dupilumab study results, then pit them against real-world evidence. Does the hype hold up outside the ivory tower?Debate how we’ll actually integrate dupilumab into our clinical arsenal. Is this a game-changer or just another tool in the kit?Explore the real impact on patient care: Will this approval mean fewer steroids, better outcomes, or simply more options for those tough-to-treat cases?Refresher course in bullous pemphigoid - diagnosis and practical treatment pearlsSo, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.For Links to articles please go to ScholarsinMedicine.com1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
--------
51:20
--------
51:20
Dermatology Debates: The Derms on Drugs Try to Change Minds
Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!
--------
44:24
--------
44:24
Serious Medical Derm: Hot Topics & Clinical Controversies—Derms on Drugs Style
Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.We break down the newest literature and answer:Does immunotherapy really help with high-risk squamous cell carcinoma?Are pemphigus patients getting more rituximab than they need?Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?Is the Mind.Px test actually helpful for picking a psoriasis biologic?What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?Which treatment factors predict scabies cure?Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!Hit play and stay on the cutting edge of medical dermatology!1. Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma2. Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial3. Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium4. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis5. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes6. Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab7. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure
--------
46:14
--------
46:14
Chronic Spontaneous Urticaria: New Trials, Hot Treatments, and Patient Pearls with Dr. Jason Hawkes
Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.We’re joined by CSU expert Dr. Jason Hawkes to discuss:-How Dupixent is changing the game for CSU and why dermatologists are leading the charge-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients-How we explain to CSU patients that they don’t need allergy testing!-Clinical pearls for work-up, navigating treatment guidelines, safety, and accessPerfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.Hit play and stay ahead on the cutting edge of CSU care!1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound2. Remibrutinib in Chronic Spontaneous Urticaria3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.
It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.
Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
USA